# ğŸ“ Question: Explain the provisions relating to compulsory licensing under the Patents Act, 1970, and discuss the Natco v. Bayer case. (10 Marks)

---

## âœï¸ Answer:

### ğŸ¯ Introduction

Compulsory licensing is a mechanism that allows the government to authorize the use of a patented invention by a third party without the patent owner's consent. This powerful tool balances exclusive patent rights with public interest, particularly access to essential medicines. The Patents Act, 1970, contains detailed provisions on compulsory licensing that reflect India's commitment to both promoting innovation and ensuring public welfare.

---

### ğŸ“Š Visual Framework: Compulsory Licensing Structure

```
Compulsory Licensing
         |
         â”œâ”€â”€ Section 84 - General Grounds (After 3 years)
         â”‚    â”œâ”€â”€ Reasonable requirements not met
         â”‚    â”œâ”€â”€ Not available at affordable price
         â”‚    â””â”€â”€ Not worked in India
         â”‚
         â”œâ”€â”€ Section 92 - Special Cases (No waiting period)
         â”‚    â”œâ”€â”€ National emergency
         â”‚    â”œâ”€â”€ Extreme urgency
         â”‚    â””â”€â”€ Public non-commercial use
         â”‚
         â””â”€â”€ Section 92A - Export
              â””â”€â”€ For countries lacking manufacturing capacity
```

---

### ğŸ“œ 3 Provisions for Compulsory Licensing

**ğŸ¯ Mnemonic: "GSE"**
- **G** - General (Section 84)
- **S** - Special Cases (Section 92)
- **E** - Export (Section 92A)

---

#### ğŸ“‹ Provision 1: Section 84 - General Grounds

**â±ï¸ Timing:** After **3 years from grant of patent**

**ğŸ‘¥ Who Can Apply:** Any interested person

##### 3 Grounds for Compulsory License

**ğŸ¯ Mnemonic: "RAW"**
- **R** - Reasonable requirements not satisfied
- **A** - Affordable price not available
- **W** - Worked in India not done

---

**Ground 1ï¸âƒ£: Reasonable Requirements Not Satisfied**

The reasonable requirements of the public with respect to the patented invention have not been satisfied.

**ğŸ’¡ What This Means:**
- ğŸ“‰ Invention not available in sufficient quantity
- ğŸ’° Not available at reasonably affordable prices
- ğŸ“Š Demand exceeds supply

---

**Ground 2ï¸âƒ£: Not Available at Reasonably Affordable Price**

The patented invention is not available to the public at a reasonably affordable price.

---

**Ground 3ï¸âƒ£: Not Worked in India**

The patented invention is not worked (manufactured) in the territory of India.

**âš¡ Important:** Simply importing doesn't satisfy working requirement. Local manufacturing encouraged.

---

##### ğŸ¤ Prior Negotiation Required (Section 84(6))

Controller won't grant compulsory license unless:
- ğŸ’¬ Applicant made efforts to obtain voluntary license
- âŒ Efforts unsuccessful within reasonable period (â‰ˆ6 months)

**âš¡ Exception:** Prior negotiation waived for:
- ğŸš¨ National emergency
- â° Extreme urgency
- ğŸ›ï¸ Public non-commercial use
- ğŸš« Anti-competitive practices

---

#### ğŸš¨ Provision 2: Section 92 - Special Cases

**âš¡ NO 3-year waiting period required**

##### 3 Circumstances for Section 92

**1. ğŸš¨ National Emergency**
**2. â° Extreme Urgency**
**3. ğŸ›ï¸ Public Non-Commercial Use**

**âœ… Examples:**
- ğŸ’Š Health epidemics (HIV/AIDS, TB, COVID-19)
- ğŸŒªï¸ Natural disasters
- âš”ï¸ War or national security threat

**ğŸ”‘ Special Feature:** No prior negotiation required.

---

#### ğŸŒ Provision 3: Section 92A - Export License

For countries lacking pharmaceutical manufacturing capacity:
- ğŸ¥ That country issues compulsory license
- ğŸ‡®ğŸ‡³ India can grant license to manufacture and export
- ğŸŒ Helps countries unable to manufacture themselves

---

### ğŸ“‹ 6 Terms and Conditions of Compulsory Licenses

**ğŸ¯ Mnemonic: "SNNPDR"**
- **S** - Scope limited
- **N** - Non-exclusive
- **N** - Non-assignable
- **P** - Predominantly domestic
- **D** - Duration limited
- **R** - Remuneration adequate

---

**Condition 1ï¸âƒ£: Limited Scope and Duration**
- License limited to purpose for which granted
- Reasonable duration (periodic review)

**Condition 2ï¸âƒ£: Non-Exclusive**
- Always non-exclusive
- Patent owner can still work patent or grant other licenses

**Condition 3ï¸âƒ£: Non-Assignable**
- Cannot be independently transferred
- Only with business/enterprise using patent

**Condition 4ï¸âƒ£: Predominantly Domestic Market**
- Production must be mainly for domestic market
- Cannot be primarily for export (except Section 92A)

**Condition 5ï¸âƒ£: Reasonable Duration**
- Not perpetual
- Subject to review

**Condition 6ï¸âƒ£: Adequate Remuneration (Section 90)**
- Licensee must pay patent owner
- Controller determines amount (typically 2-7% of net sales)
- Considers: Economic value, nature of invention, public health

---

### âš–ï¸ Landmark Case: Natco Pharma v. Bayer (2012) â­â­â­

#### ğŸ“‹ Case Details

**ğŸ’Š Drug:** Nexavar (Sorafenib Tosylate) - Cancer drug (kidney/liver)  
**ğŸ¢ Patentee:** Bayer Corporation (Germany)  
**ğŸ­ Applicant:** Natco Pharma (India)  
**ğŸ“… Decision:** March 2012  
**ğŸ† Status:** India's FIRST compulsory license

---

#### ğŸ“– 6 Critical Facts

**Fact 1ï¸âƒ£: Exorbitant Pricing**
- ğŸ’¸ Bayer's price: **â‚¹2.8 lakh per month** per patient
- âš ï¸ Unaffordable for most Indians

**Fact 2ï¸âƒ£: Limited Availability**
- âŒ Only **2% of patients** who needed drug could access it
- ğŸ“Š Only ~200 patients per month in India

**Fact 3ï¸âƒ£: Not Worked in India**
- ğŸ“¥ Bayer was importing, not manufacturing locally
- âŒ No production facility in India

**Fact 4ï¸âƒ£: Natco's Offer**
- ğŸ’° Offered at **â‚¹8,800 per month**
- ğŸ“‰ **97% price reduction**
- ğŸ¯ Make available to thousands

**Fact 5ï¸âƒ£: Prior Negotiation Attempted**
- ğŸ’¬ Natco approached Bayer for voluntary license
- âŒ Negotiations failed

**Fact 6ï¸âƒ£: Patient Need**
- ğŸ¥ Life-saving drug for advanced cancer
- â±ï¸ No alternative treatment available

---

#### ğŸ’¬ Bayer's 5 Defense Arguments

**1. ğŸ’° High R&D Costs:** Spent $1 billion - price justified
**2. ğŸ Patient Assistance Program:** Free drug for poor patients
**3. ğŸ“Š Small Market:** Low sales due to small patient population
**4. ğŸ“¥ Import = Working:** Importing satisfies requirement
**5. ğŸ’µ Reasonable Price:** Price reasonable for R&D investment

---

#### âš–ï¸ Controller's Decision - LICENSE GRANTED âœ…

##### 4 Key Findings

**Finding 1ï¸âƒ£: Reasonable Requirements NOT Met**
- âŒ Only 2% access rate insufficient
- ğŸ’¸ â‚¹2.8 lakh unaffordable for most Indians
- ğŸ Patient assistance program inadequate (only 200 patients)
- ğŸš« Reasonable requirements of public not satisfied

**Finding 2ï¸âƒ£: NOT Reasonably Affordable**
- ğŸ‡®ğŸ‡³ â‚¹2.8 lakh not reasonable in Indian context
- ğŸ“Š Per capita income much lower than developed countries
- âš–ï¸ "Reasonable" must be interpreted locally, not globally

**Finding 3ï¸âƒ£: NOT Worked in India**
- ğŸ“¥ Merely importing - no local manufacturing
- ğŸ­ Patents Act encourages local production
- ğŸ“œ Section 83: Patents not granted just for importation

**Finding 4ï¸âƒ£: Prior Negotiation Done**
- ğŸ’¬ Natco had approached Bayer
- âŒ Bayer offered unreasonable terms
- âœ… Requirement satisfied

---

#### ğŸ“‹ 5 Terms of the Compulsory License

**Term 1ï¸âƒ£: Royalty Payment**
- ğŸ’° Natco must pay Bayer **6% of net sales**

**Term 2ï¸âƒ£: Price Cap**
- ğŸ’µ Natco must sell at **â‚¹8,800 per month**

**Term 3ï¸âƒ£: Minimum Supply**
- ğŸ“Š Supply to at least **600 patients/month** initially

**Term 4ï¸âƒ£: Quality Assurance**
- âœ¨ Ensure good quality
- âœ… Comply with regulatory standards

**Term 5ï¸âƒ£: Free Supply Obligation**
- ğŸ Provide drug **free to 600 patients annually** who cannot afford

---

### ğŸŒŸ 8 Significance Points of Natco Case

**ğŸ¯ Mnemonic: "FIAT WIEP"**
- **F** - First CL in India
- **I** - Interpretation of "affordable"
- **A** - Access to medicines
- **T** - TRIPS flexibilities used
- **W** - Working requirement clarified
- **I** - India's policy direction
- **E** - Evergreening prevented
- **P** - Price reduction (97%)

---

**1ï¸âƒ£ First Compulsory License:**
First CL granted under India's post-TRIPS patent regime.

**2ï¸âƒ£ Access to Medicines:**
- ğŸ’¸ Price: â‚¹2.8 lakh â†’ â‚¹8,800 (97% reduction)
- ğŸ“ˆ Availability: 200 â†’ thousands of patients

**3ï¸âƒ£ "Reasonably Affordable" Interpretation:**
Must be interpreted in Indian economic context.

**4ï¸âƒ£ "Working" Requirement Clarified:**
Importing â‰  Working. Local manufacturing encouraged.

**5ï¸âƒ£ Balance of Interests:**
- ğŸ’° Patent rights protected (6% royalty)
- ğŸ’Š Public health served (affordable access)
- ğŸ”¬ Innovation incentives maintained

**6ï¸âƒ£ Policy Direction:**
Strong signal about India's public health priorities.

**7ï¸âƒ£ TRIPS Flexibilities:**
Demonstrated effective use of TRIPS flexibilities.

**8ï¸âƒ£ Global Precedent:**
Model for other developing countries.

---

#### â© Aftermath

**âš–ï¸ Appeal:**
Bayer appealed to IPAB. IPAB **upheld** compulsory license (2013) with minor modifications.

**âœ… Impact:**
- ğŸ’Š Natco made Nexavar affordable
- ğŸ¥ Thousands gained access to treatment
- ğŸ“‹ Precedent established
- ğŸŒ Demonstrated TRIPS flexibilities work

---

### ğŸ¯ Conclusion

Compulsory licensing is a critical tool for balancing patent rights with public interest, particularly in ensuring access to essential medicines. The Natco v. Bayer case demonstrated that India is willing to use this tool effectively when patented drugs are unaffordable or unavailable.

**4 Key Lessons:**
1. âš–ï¸ Patent rights are not absolute
2. ğŸ’Š Public health can override exclusive rights
3. ğŸŒ TRIPS flexibilities can be used effectively
4. ğŸ’° Reasonable compensation still provided

For developing countries like India, compulsory licensing remains an essential safeguard to ensure that patent protection doesn't come at the cost of access to life-saving medicines. The Natco case serves as a model for how this balance can be achieved in practice.

---

**ğŸ“š Key Statutory Provisions:**
- **Section 84:** General grounds (3 grounds: RAW)
- **Section 92:** Special cases (3 circumstances)
- **Section 92A:** Export license
- **Section 90:** Remuneration (2-7% typical)

**âš–ï¸ Key Case: Natco v. Bayer (2012)**
- ğŸ’Š Drug: Nexavar (cancer)
- ğŸ’¸ Price reduced: â‚¹2.8L â†’ â‚¹8,800 (97%)
- ğŸ’° Royalty: 6%
- ğŸ† First CL in India
- âœ… Upheld by IPAB (2013)

**ğŸ’¡ Remember:** "RAW" grounds, "GSE" provisions, Natco reduced price by 97%!
